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wo the Editor: Treatment of in-stent restenosis (ISR) remains a
hallenge (1–5). Bare-metal stents provide excellent angiographic
esults, but are shadowed by high restenosis rates. Accordingly,
hey are reserved for patients with large vessels, edge-ISR, or those
nsuitable for long-term dual antiplatelet therapy (1–3). Currently,
rug-eluting stents (DES) represent the therapy of choice for ISR
2,3). Nevertheless, 10% to 20% of patients receiving DES for ISR
evelop recurrences (2,3). The best management for patients with
ecurrent ISR in a segment previously treated with 2 stents remains
nsettled. Furthermore, the pathophysiological consequences of a
hird metal layer on human coronary arteries are unknown. We
escribe the long-term clinical, angiographic, and intravascular
ltrasound (IVUS) results of a new stent implantation in patients
uffering recurrences after stenting for ISR.
From April 2004 to June 2008, 21 consecutive patients under-
oing stent implantation for recurrent ISR after stenting for ISR
third stent on the same coronary segment) were included. The
tudy protocol was approved by the Institutional Ethical Commit-
ee, and all patients gave informed consent. Care was paid to
ptimize final results. Residual balloon waists were prospectively
ssessed, and when detected, aggressively managed with high-
ressure dilations with noncompliant balloons. IVUS was per-
ormed before and after the procedure (4). Troponin, creatine
inase levels (MB if abnormal), and electrocardiograms were
erially obtained. Previous angiograms were reviewed to determine
ocations of previous stents and sites of ISR. Stent overlap was
isually assessed. Views that better displayed ISR lesions were
dentified and repeated at 9-month follow-up. An automatic
ngiographic edge-detection system (MEDIS, CMS 4.0, Leiden,
he Netherlands) was used. Suboptimal results were defined as a
esidual diameter stenosis 20%. IVUS were obtained from
otorized (0.5 mm/s) pull-backs. Lumen and stent areas were
easured at 1-mm intervals. Neointima volume was calculated as
tent minus lumen volume (3). Stent expansion was calculated as
inimal stent area/mean reference lumen area  100. Underex-
ansion was defined as stent expansion 80%. The presence of
alcium (1 to 4 quadrants) was analyzed along the stent length.
spirin and clopidogrel were recommended for 1 year. Major
vents (death, myocardial infarction, and target vessel revascular-
zation) were verified against source documentation. Target vessel
ailure included clinical events or angiographic ISR. The Fisher
xact test and paired/unpaired Student t tests were used as
equired. Event-free survival was estimated by Kaplan-Meier
nalysis. Cox analyses were used to study event predictors. A value
f p  0.05 was considered statistically significant.
Clinical and angiographic characteristics are summarized in
able 1. The results of the second stent were suboptimal in 4 cases sespite high deployment pressures. The same occurred after the
hird (index) procedure: despite higher inflation pressures (20  4
tm, p  0.05 vs. second stent), residual stenosis was 17  11% (4
atients had suboptimal results). In 6 cases, a residual waist was
oticed during last balloon inflation. Before intervention, IVUS
tudies of adequate quality to assess expansion were obtained in 7
atients. Minimal stent area was 5.9  2.4 mm2 and stent
xpansion 64.5  19.8%. Neointimal volume was 53.2  41.2
m3 and stent volume was 147 40 mm3 (33 13% occupied by
eointima). Severe calcification (maximal 2.4 0.6 quadrants) was
isualized behind all stents. After interventions, data of stent
xpansion were obtained in 13 patients. Minimal stent area was
.8  1.7 mm2, stent expansion 67.3  15%, and final stent
olume 178  65 mm3. However, in the 6 patients with paired
tudies (adequate before/after comparisons), minimal stent area
mproved (5.2  1.8 mm2 vs. 6.6  1.7 mm2, p  0.03), whereas
he changes in stent expansion (60.5  18.4% vs. 75.4  15.4%,
 0.06) and stent volume (144  45 mm3 vs. 182  59 mm3,
 0.27) were not statistically significant. Procedural success was
btained in all patients, and no complications occurred (no case
resented troponin increases). At last clinical follow-up (median
54 days, interquartile range 77 to 818 days), 2 patients had died.
n 1 patient, recurrent ISR developed and the patient underwent a
ourth stent implantation, but eventually required surgery (962
ays after the index procedure, without target lesion ISR) for left
ain and multivessel disease, and died after a perioperative
yocardial infarction. The second patient died 5 days after a
-wave target vessel-related myocardial infarction, 53 days after
he procedure (probable stent thrombosis, on clopidogrel). A
-wave myocardial infarction occurred on day 6, caused by a
ide-branch loss, jailed, but emerging from a patent stent. No
dditional patient suffered adverse events. At 1 year, the event-free
urvival was 90% (95% confidence interval: 77% to 99%). Late
ngiography (median 274 days, interquartile range 196 to 347
ays) was obtained in 14 of 16 patients (88% of those eligible,
ollow-up 9 months). Recurrent ISR was detected in 3 patients:
required new DES implantation (the patient who died after
urgery); 1 had asymptomatic ISR in a small distal vessel left
ntreated; the third patient, with moderate, asymptomatic edge-
SR (fractional flow reserve 0.83), was also untreated. IVUS at late
ollow-up (7 patients) showed a minimal lumen area of 4.2  0.7
m2, a neointimal volume of 1.2  2.9 mm3 obstructing only 0.5
1.2% of stent volume. On Cox analysis, of all clinical, angio-
raphic, and IVUS variables, only time to ISR (p  0.01) and
VUS-detected stent underexpansion (p  0.043) were associated
ith target vessel failure.
This study shows that DES implantation for recurrences aftertenting for ISR is safe and effective. In our series, very high
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September 8, 2009:1036–40ressures were required to obtain satisfactory angiographic results,
lthough suboptimal results remained in some patients. On IVUS,
hese patients presented severely underexpanded stents, which
emained relatively underexpanded after the third stent despite
igh-pressure dilations. Heavily calcified vessels seem to explain
his phenomenon. Previous studies showed that DES underexpan-
ion predisposes to ISR (4). Our findings emphasize the impor-
ance of optimizing final results in patients with ISR because
nderexpanded stents may not only trigger recurrences but also
onstitute a challenging substrate for reinterventions. In our series,
owever, late clinical outcome in patients with complex lesions and
ecalcitrant ISR was favorable, with a 1-year event-free survival of
Clinical, Angiographic, and Procedural CharacteristicsTable 1 Clinical, Angiographic, and Procedural Ch
Age, yrs
Female sex
Diabetes/hyperlipidemia/hypertension
Number of previous target vessel PCIs
Time from first to second stent, days ()
Time from second to third stent, days ()
Unstable/stable angina
Left ventricular ejection fraction, %
Coronary artery (LM/LAD/LCX/RCA/SVG)
B2-C lesion
Mehran classification (I/II/III/IV)
First stent
Stent type (BMS/DES)
Second stent
Stent type (BMS/DES)
Visual overlap (second to first stent), mm
Maximal pressure, atm
Balloon diameter (balloon/artery), mm
Third stent
Stent type (BMS/DES)
Stent length, mm
Visual overlap (third to second stent), mm
Maximal pressure, atm
Balloon diameter (balloon/artery), mm
Quantitative angiography
Before index procedure
Reference vessel diameter, mm
Minimal lumen diameter, mm
Stenosis, % of lumen diameter
Lesion length, mm
After index procedure
Reference vessel diameter, mm
Minimal lumen diameter, mm
Stenosis, % of lumen diameter
Acute gain, mm
At follow-up
Reference vessel diameter, mm
Minimal lumen diameter, mm
Stenosis, % of lumen diameter
Lesion length, mm
Restenosis, %
Late loss, mm
Loss index
Net gain, mm
Values are mean SD, n (%), or () median and interquartile range.
implanted in the left main vessel after ISR of 2 previous DES.
BMS  bare-metal stent(s); DES  drug-eluting stent(s); EES  e
LCX  left circumflex coronary artery; LM  left main; PCI  percuta
coronary artery; SES  sirolimus-eluting stent(s); SVG  saphenous v0%. We believe that the aggressive dilation strategy coupled with rhe systematic use of DES played a major role in explaining this
enign outcome.
In the ISAR–DESIRE (Intracoronary Stenting or Angioplasty
or Restenosis Reduction–Drug-Eluting Stents for In-Stent Re-
tenosis) trial, Kastrati et al. (2) found that the incidence of ISR
as significantly reduced after sirolimus-eluting stent and
aclitaxel-eluting stent implantation as compared with balloon
ngioplasty. The RIBS-II (Restenosis Intrastent: Balloon angio-
lasty versus elective sirolimus-eluting Stenting II) randomized
tudy showed the superiority of DES over balloon angioplasty and
onfirmed the striking antiproliferative efficacy of DES in this
etting (3). No previous study, however, has yet analyzed the
ristics
64 10
6 (29)
7 (33), 16 (76), 16 (76)
2.6 0.7
266 (154–444)
822 (335–2,345)
9 (43)/12 (57)
66 12
1 (5)/10 (48)/2 (9)/6 (29)/2 (9)
16 (76)
11 (52)/7 (33)/2 (10)/1 (5)
18/3 (3 PES)
7/14 (10 SES, 3 PES, 1 EES)
16.8 8
17.3 2.7
3.04 0.4 (1.29 0.3)
1*/20 (5 SES, 9 PES, 6 EES)
20.1 11
14.2 8.3
20 4
3.07 0.4 (1.21 0.2)
In-lesion analysis) (In-segment analysis)
(n  21) (n  21)
2.68 0.7 2.64 0.7
1.01 0.4 1.01 0.4
62 12 61 13
10.1 10 10.1 10
(n  21) (n  21)
3.00 0.8 2.93 0.9
2.66 0.7 2.41 0.8
12 9.1 17 11
1.65 0.8 1.40 0.7
(n  14) (n  14)
2.89 0.8 2.69 0.8
2.17 0.7 1.94 0.8
24 19 29 18
6.9 6.1 6.9 6.1
2/14 (14) 3/14 (21)
0.45 0.7 0.40 0.6
0.22 0.5 0.31 0.6
1.09 0.7 0.86 0.7
ative angiographic analyses were performed in the worst view. *BMS
us-eluting stent(s); LAD  left anterior descending coronary artery;
coronary intervention; PES  paclitaxel-eluting stent(s); RCA  right
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September 8, 2009:1036–40n a coronary segment already housing a double stent layer.
lthough dilation, with high-pressure noncompliant balloons, has
een advocated in patients with underexpanded stents, the results
f this strategy remains unsettled. Special care is required to
revent balloon slippage during these aggressive dilations. Alter-
ative techniques to overcome resistant areas of stent underexpan-
ion have not been systematically evaluated. Cutting balloon
ngioplasty and buddy-wire techniques have been proposed to
odify local wall stress, but again, their real value to tackle severe
tent underexpansion remains undefined (5). Finally, rotational
therectomy has been proposed in this setting, but the risks
ssociated with this highly aggressive approach seem rarely justi-
ed. In patients with ISR and unexpandable stents, the use of
dditional stenting should not be routinely advocated. However,
onsidering that in this scenario minor neointimal growth could
rigger recurrences, DES implantation, coupled with aggressive
ttempts to expand the underlying stents, seems reasonable. In
onclusion, in patients with recurrences after stenting for ISR,
ES implantation provides satisfactory long-term clinical, angio-
raphic, and IVUS results.
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intravascular ultrasound.Letters to the Editoreveloping Sustainable
ardiovascular Care for
ow-Resource Nations
e read with keen interest the commentary by Weaver (1)
utlining the new international strategy of the American College
f Cardiology (ACC). We note, however, the failure of this new
trategic vision to address the greater need for developing sustain-
ble local infrastructure in emerging economies.
According to the World Health Organization (WHO), cardio-
ascular disease (CVD) is responsible for 17 million deaths
nnually, accounting for one-third of all global deaths, with nearly
5% of the global CVD mortality and disease burden occurring in
eveloping countries (2). That is mainly due to the absence of
ppropriate infrastructure for specialized diagnostic and treatment
ervices for CVDs.
It is estimated that by 2015, the number of deaths due to
oncommunicable diseases in Africa will exceed those due to
ommunicable diseases (3). The majority of these shifts will occur
n the emerging CVD pandemic. By year 2020, the CVD mortalitynd by 126% in women (3). Furthermore, by 2025, prevalence
ates for diabetes mellitus in developing countries will increase by
70%, from 84 million to 228 million, or more than 75% of the
lobal burden of diabetes (3). The crisis at hand presents a
ombination of moral, socioeconomic, and security challenges for
he global community.
This is why we believe that organizations such as the ACC can
lay a significant role in facilitating the development of local
nfrastructure and sustainable programs in developing economies.
his is the concept that underlies the mission of the Heart
nstitute of the Caribbean, where we have shown that with careful
lanning, smart design, and appropriate use of technology, sus-
ainable and affordable high-quality cardiovascular care anchored
n aggressive prevention and treatment strategies can be developed
n low-resource economies (4). We are now expanding our model
o countries in Africa such as Nigeria, Ghana, and Tanzania. We
ee and encourage a major role for the ACC in promoting such
odels of cardiovascular care in developing countries. The type of
are that is taken for granted in the U.S. and Europe can indeed be
vailable globally.
The ACC must also explore collaborations in developing
ountries that will foster dialogue with cardiovascular specialists
nd encourage appropriate capacity building and development of
ulticultural competencies (5).
